

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,179,625 B2
APPLICATION NO. : 10/758672
DATED : February 20, 2007
INVENTOR(S) : Hui-Quan Han et al.

Page 1 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Drawings:

At Sheet 20, Fig. 9, left graph label, "Gastroenmius" should be -- Gastrocnemius --.

At Column 2, line 2, "conjugatin" should be -- conjugation --.

At Column 7, line 3, "cacheixia" should be -- cachexia --.

At Column 7, lines 19-20, "does-dependent" should be -- dose-dependent --.

At Column 7, line 41, "molecules" should be -- molecule --.

At Column 8, line 42, "encompasses" should be -- encompass --.

At Column 10, line 28, "agents" should be -- agent --.

At Column 10, line 56, "tinder" should be -- under --.

At Column 10, line 58, "0.01 5M" should be -- 0.015 M --.

At Column 13, line 6, "a its hydropathic" should be -- a hydropathic --.

At Column 14, line 42, "IN" should be -- In --.

At Column 17, line 22, "derivative" should be -- derivatize --.

At Column 19, line 33, "(I)" should be -- (1) --.

At Column 19, lines 63-64, "normative" should be --nonnative --.

At Column 23, line 18, "stricture" should be -- structure --.

At Column 29, line 39, "La Jolla" should be -- La Jolla, --.

At Column 29, line 66, "Univeristy Boulavard" should be -- University Boulevard --.

At Column 32, line 28, "call be" should be -- can be --.

At Column 33, line 3, "Synthesis." should be -- *Synthesis*,--.

At Column 33, line 20, "example, using an" should be -- example, an --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,179,625 B2
APPLICATION NO. : 10/758672
DATED : February 20, 2007
INVENTOR(S) : Hui-Quan Han et al.

Page 2 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 34, line 63, "molecule" should be -- molecules --.

At Column 35, line 50, "humanized" should be -- humanized, --.

At Column 36, line 31, "1536" should be -- 1536, --.

At Column 40, line 5, "set of has" should be -- set of test molecules has --.

At Column 42, line 31, "construct can" should be -- construct that can --.

At Column 42, line 32, "vector(such as the pAS2-1 form Clontech)" should be -- vector (such as the pAS2-1 from Clontech) --.

At Column 45, line 21, "difluisal" should be -- diflunisal --.

At Column 46, lines 6-7, "pyrazalones" should be -- pyrazolones --.

At Column 46, line 31, "AFPS60" should be -- AFP860 --.

At Column 47, line 65, "cephalosporilns" should be -- cephalosporins --.

At Column 49, line 44, "huE3 α such" should be -- such huE3 α --.

At Column 50, line 20, "pH typically" should be -- pH, typically --.

At Column 50, line 64, "maybe" should be -- may be --.

At Column 52, line 43, "19811" should be -- 1981 --.

At Column 53, lines 19-20, "pharmaceuticalcompositions" should be -- pharmaceutical compositions --.

At Column 53, line 38, "iii vitro" should be -- *in vitro* --.

At Column 63, line 17, "clone of was" should be -- clone was --.

At Column 63, lines 41-42, "activities" should be -- activity --.

At Column 65, lines 13-14, "*Edition*", *Edition*," should be -- *Edition*, --.

At Column 65, line 17, "an recombinant" should be -- in recombinant --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,179,625 B2
APPLICATION NO. : 10/758672
DATED : February 20, 2007
INVENTOR(S) : Hui-Quan Han et al.

Page 3 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 66, line 6, "concentrations" should be -- concentration --.

At Column 67, line 32, "manufacture's" should be -- manufacturer's --.

At Column 67, line 61, "50 ug/ml" should be -- 50 µg/ml --.

At Column 68, line 3, "Phosphalmager" should be -- a Phosphalmager --.

At Column 68, line 23, "MgCl2" should be -- MgCl₂ --.

At Column 68, line 32, "Phsophoimager" should be -- Phosphalmager --.

At Column 69, line 47, "MgCl2" should be -- MgCl₂ --.

At Column 69, line 51, "muscles" should be -- muscle --.

At Column 69, line 64, "protein ubquitination" should be -- protein ubiquitination --.

At Column 70, line 31, "50-58 °C for 45 seconds, and 72°C for 1 minutes" should be -- 50- 58°C for 45 seconds, and 72°C for 1 minute --.

At Column 70, line 31, "avaiblae" should be -- available --.

At Column 70, line 32, "1578553," should be -- 1578553 --.

At Column 71, line 2, "was" should be -- were --.

At Column 71, line 13, "were" should be -- was --.

At Column 71, line 28, "seperating" should be -- separating --.

At Column 71, lines 38-39, "SEQ ID NO: 29)" should be -- (SEQ ID NO: 29) --.

At Column 71, line 40, " minutes" should be -- minute --.

At Column 71, lines 41-42, "Mannheim cat: 1578553," should be -- Mannheim, cat: 1578553 --.

At Column 71, line 58, "tehrere" should be -- there --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,179,625 B2
APPLICATION NO. : 10/758672
DATED : February 20, 2007
INVENTOR(S) : Hui-Quan Han et al.

Page 4 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 71, line 62, "decease" should be -- decrease --.


At Column 74, line 2, "is critical" should be -- is a critical --.

In the Claims:

At Column 165, line 47, "least percent" should be -- least 95 percent --.

Signed and Sealed this

Third Day of July, 2007

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looping initial "J" and a distinct "D".

JON W. DUDAS
Director of the United States Patent and Trademark Office